Book contents
- Dispatches from the Land of Alzheimer’s
- Reviews
- Dispatches from the Land of Alzheimer’s
- Copyright page
- Dedication
- Lost in Thought
- Contents
- Acknowledgments
- Prologue
- 1 Physician Heal Thyself
- 2 Evaluating New Advances in Alzheimer’s Research
- 3 Alzheimer’s Dementia or Alzheimer’s Disease
- 4 The First Patient with Alzheimer’s Disease
- 5 Kidnapped in Kinshasa
- 6 Smell, Disgust, and Alzheimer’s
- 7 Apolipoprotein-4 (APOE-4)
- 8 Lost in the Fog of Alzheimer’s
- 9 My Father’s “Stuff”
- 10 Face Blindness during a Pandemic
- 11 Biomarkers for Alzheimer’s Disease
- 12 Olfactory Impairment in Covid-19 and Alzheimer’s
- 13 Alzheimer’s Disease and Work
- 14 Crossword Controversies
- 15 Can Loneliness Increase Risk for Dementia?
- 16 Excessive Laxative Use and Dementia
- 17 Dog Dementia (Canine Cognitive Dysfunction)
- 18 The Possible Role of Brain Inflammation in Alzheimer’s Disease May Be More Significant in APOE-4 Carriers
- 19 Surprisingly Good News about the Acetylcholinesterase Inhibitors (Donepezil, Rivastigmine, and Galantamine)
- 20 More about the Importance of Exercise
- 21 Rolling on the River
- 22 The MIND Diet Revisited
- 23 My Photographs, Then and Now
- 24 Does Cataract Surgery Really Decrease the Risk of Dementia?
- 25 Hearing Loss, Aphasia, and Dementia
- 26 To Sleep, Perchance to Dream
- 27 The Amyloid Hypothesis Is Not Dead, but It May Be Gasping for Breath
- 28 Could Lecanemab Offer a Ray of Hope?
- 29 A Fatal Case of Multiple Brain Hemorrhages Associated with Lecanemab
- 30 Cerebral Amyloid Angiopathy (CAA)
- 31 Hitting the Sweet Spot in the Spectrum of Alzheimer’s Disease for Future Trials of Anti-Amyloid Medications
- 32 Disappointing Results of Two Human Trials of Monoclonal Antibodies in Parkinson’s Disease
- 33 Repurposing Old Drugs for Alzheimer’s Treatment
- 34 Writing While Impaired
- 35 Spreading the Word
- 36 Saying Goodbye to Lizzie G
- 37 Amyloid and Tau PET Scans of My Brain
- 38 Running on a Field of Dreams
- 39 Living in the Moment with Alzheimer’s
- Index
- Plate Section (PDF Only)
- References
29 - A Fatal Case of Multiple Brain Hemorrhages Associated with Lecanemab
Published online by Cambridge University Press: 19 January 2024
Book contents
- Dispatches from the Land of Alzheimer’s
- Reviews
- Dispatches from the Land of Alzheimer’s
- Copyright page
- Dedication
- Lost in Thought
- Contents
- Acknowledgments
- Prologue
- 1 Physician Heal Thyself
- 2 Evaluating New Advances in Alzheimer’s Research
- 3 Alzheimer’s Dementia or Alzheimer’s Disease
- 4 The First Patient with Alzheimer’s Disease
- 5 Kidnapped in Kinshasa
- 6 Smell, Disgust, and Alzheimer’s
- 7 Apolipoprotein-4 (APOE-4)
- 8 Lost in the Fog of Alzheimer’s
- 9 My Father’s “Stuff”
- 10 Face Blindness during a Pandemic
- 11 Biomarkers for Alzheimer’s Disease
- 12 Olfactory Impairment in Covid-19 and Alzheimer’s
- 13 Alzheimer’s Disease and Work
- 14 Crossword Controversies
- 15 Can Loneliness Increase Risk for Dementia?
- 16 Excessive Laxative Use and Dementia
- 17 Dog Dementia (Canine Cognitive Dysfunction)
- 18 The Possible Role of Brain Inflammation in Alzheimer’s Disease May Be More Significant in APOE-4 Carriers
- 19 Surprisingly Good News about the Acetylcholinesterase Inhibitors (Donepezil, Rivastigmine, and Galantamine)
- 20 More about the Importance of Exercise
- 21 Rolling on the River
- 22 The MIND Diet Revisited
- 23 My Photographs, Then and Now
- 24 Does Cataract Surgery Really Decrease the Risk of Dementia?
- 25 Hearing Loss, Aphasia, and Dementia
- 26 To Sleep, Perchance to Dream
- 27 The Amyloid Hypothesis Is Not Dead, but It May Be Gasping for Breath
- 28 Could Lecanemab Offer a Ray of Hope?
- 29 A Fatal Case of Multiple Brain Hemorrhages Associated with Lecanemab
- 30 Cerebral Amyloid Angiopathy (CAA)
- 31 Hitting the Sweet Spot in the Spectrum of Alzheimer’s Disease for Future Trials of Anti-Amyloid Medications
- 32 Disappointing Results of Two Human Trials of Monoclonal Antibodies in Parkinson’s Disease
- 33 Repurposing Old Drugs for Alzheimer’s Treatment
- 34 Writing While Impaired
- 35 Spreading the Word
- 36 Saying Goodbye to Lizzie G
- 37 Amyloid and Tau PET Scans of My Brain
- 38 Running on a Field of Dreams
- 39 Living in the Moment with Alzheimer’s
- Index
- Plate Section (PDF Only)
- References
Summary
However, there is a darker side to anti-amyloid monoclonal antibodies including lecanemab. ARIA, an acronym for amyloid-related imaging abnormalities, have occurred in all trials of anti-amyloid MABs. They occur in two forms, swelling (edema) of the brain (ARIA-E) and microhemorrhages (ARIA-H). Most of the time they are harmless and without symptoms, and they usually resolve within a month or two after stopping the drug. Rarely, they can be severe. As described in a case study, I was one of the subjects in the aducanumab trial who had severe ARIA of both types, swelling and bleeding. I required ICU care for two days, but I eventually fully recovered over the next few months. So far, three research subjects have died during the lecanemab clinical trial.
Keywords
- Type
- Chapter
- Information
- Dispatches from the Land of Alzheimer's , pp. 119 - 122Publisher: Cambridge University PressPrint publication year: 2024
References
AHEAD Study. Lecanemab for people with increased risk of Alzheimer’s disease. www.alzheimers.gov/clinical-trials/ahead-study-ban2401-people-increased-risk-alzheimers-disease (accessed 2/12/2023).Google Scholar
VandeVrede, L, Gibbs, DM, Koestler, M, et al. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab. Alzheimers Dement 2020; 12: e12101. https://doi.org/10.1002/dad2.12101 (open access).Google Scholar
Reish, NJ, Jamshidi, P, Stamm, B, et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med 2023; 388: 478. https://doi.org/10.1056/NEJMc2215148.CrossRefGoogle Scholar
Jäkel, L, Anna, M, De Kort, AM, Schreuder, FHBM, et al. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement 2022, 18: 10–28. https://doi.org/10.1002/alz.12366 (open access).CrossRefGoogle ScholarPubMed